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ABSTRACT 
 
INTRODUCTION: 
Adenocarcinoma of the colon is the most common malignancy of 
the gastrointestinal tract. VEGF is an important regulator of tumor 
angiogenesis and is associated with metastasis and poor prognosis5. Thus, 
assessing VEGF expression is colorectal cancer can help in determining 
the prognosis. In this study, an attempt has been made to study the 
expression of VEGF in colorectal malignancies, and to compare it with 
various clinicopathological parameters. 
 
AIMS & OBJECTIVES 
• To study the epidemiological aspects of colorectal cancer in 
patients attending Rajiv Gandhi Government General Hospital 
from July 2013 – July 2015. 
• To assess the expression of VEGF in colorectal cancer. 
To compare with the clinicopathological parameters and to assess 
the prognostic significance.  
 
MATERIALS AND METHODS: 
We received 147 cases of resected specimens of colorectal 
carcinomas, during the period between July 2013 to July 2015. 
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INTRODUCTION 
 
Adenocarcinoma of the colon is the most common malignancy of the 
gastrointestinal tract. Malignant epithelial tumors of colon and rectum accounts 
for 85% of all cancers worldwide.1,2 
 
Colorectal cancer is a disease of late middle age and elderly individuals 
with a peak incidence at 60-70 with a male preponderance. It is the third most 
common cancer in males and second most common cancer in females. 1,3 
 
Classic adenoma-carcinoma sequence constitutes for about 80% 
cases4.The prognosis depends mainly on the stage of the disease. 
Approximately 30% cases with colorectal cancer have metastasis at the time of 
first presentation. 
 
Tumors require neovascularisation for growth and metastasis. VEGF is 
an important regulator of tumor angiogenesis and is associated with metastasis 
and poor prognosis5. VEGF induces vascular permeability and angiogenesis. 
Adenomas do not express VEGF. 
 
Thus, assessing VEGF expression is colorectal cancer can help in 
determining the prognosis. Therapies targeted on VEGF receptors can improve 
4um thick sections were taken and stained with hematoxylin and 
eosin.  50 random cases were selected for immunohistochemical studies 
with VEGF. 
 
RESULTS: 
• The median age at presentation is 60 years 
• Maximum number of cases occurred in the age group of 50-60 
years 
• There is a male preponderance -85 cases (57.8%) 
• Left sided tumors are more common-104 cases (70.7%) 
• 54% cases had tumors less than 5 cm in greatest dimension 
• Commonest gross appearance is ulceroproliferative-92 cases 
(62.6%) followed by the ulcerative type-23 cases(15.6%) 
• Most common histopathological subtype is Infiltrating 
adenocarcinoma-123 cases (83.7%). 
• Commonest grade is moderately differentiated-95 cases (64.6%) 
• 53 cases(36.1%) belonged to Astler-Coller stage C2. 
• 66 cases(44.9%) had lymph node involvement 
• 74 cases(50.3%) had lymphatic invasion 
• 67 cases(45.6%) had vascular invasion 
• 76 cases(51.7%) had tumor infiltrating lymphocytes 
• Resected margins were free in 147(97.3%) cases 
• Out of 147 cases, immunohistochemical analysis was done for 
expression of VEGF in 50 cases. 
• 9(18%), 20(40%) and 21(42%) cases had 1+,2+ and 3+ levels of 
VEGF expression respectively 
• Statistically significant association is present between VEGF 
expression and factors like presence of lymphatic invasion, 
vascular invasion, lymph node metastasis and stage of the tumor. 
 
KEY WORDS: 
Vascular Endothelial Growth Factor(VEGF), Neovascularisation, 
Immunohistochemistry 
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survival. VEGF expression in the cytoplasm can be determined 
immunohistochemically by using monoclonal antibodies. 
 
In this study, an attempt has been made to study the expression of VEGF 
in colorectal malignancies, and to compare it with various clinicopathological 
parameters. 
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AIMS & OBJECTIVES 
 
• To study the epidemiological aspects of colorectal cancer in patients 
attending Rajiv Gandhi Government General Hospital from July 2013 – 
July 2015. 
 
• To assess the expression of VEGF in colorectal cancer. 
 
• To compare with the clinicopathological parameters and to assess the 
prognostic significance. 
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REVIEW OF LITERATURE 
 
INTRODUCTION: 
  Colorectal carcinoma is one of the common malignancy of the 
gastrointestinal tract. It has a peak age incidence of 60-70 years. The classic 
adenoma-carcinoma sequence accounts for about 80% cases. About 30% 
patients diagnosed with colorectal carcinoma have regional or distant 
metastasis at the time of first presentation. 
 
Tumors require neovascularisation for growth and metastasis. VEGF is 
an important regulator of tumor angiogenesis and promotes regional and distant 
metastasis, thereby reducing survival. 
 
VEGF can induce vasculogenesis and lymphangiogenesis. Adenomas do 
not express VEGF. Thereby assessing the expression of VEGF in colorectal 
malignancies can help in determining the prognosis and   in improving patient 
survival. 
 
EPIDEMIOLOGY: 
 Colorectal cancer is an important public health problem and a major 
cause of morbidity and mortality throughout the world6.   There is a large 
geographic difference in global distribution of colorectal cancer. Countries with 
high risk include Australia, New Zealand, Canada and those with low risk 
include China, India, Africa and South America7. 
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 Global age standardized rates of colorectal carcinoma incidence are 
higher in men than in women (19.1/1,00,000 in men and 14.4/1,00,000 in 
women)8 
 
 Of all the cases reported worldwide, incidence in developed world 
accounts for about 63% of cases9.  Incidence rates varies upto 10 fold between 
countries with the highest rates and those with lowest rates10,11. Most colorectal 
cancers arise from benign adenomatous polyps lining the wall of the bowel12. 
Development of colorectal cancer is a multistep process13. 
 
INCIDENCE IN INDIA 
 In India, the annual incidence rates for colon and rectal cancer in men 
are 4.4 and 4.1/100000 respectively. The AAR for colon cancer in women is 
3.9/100000.Colon cancer ranks eighth and rectal cancer ranks ninth among 
men. In women, rectal cancer does not figure in top ten, whereas colon cancer 
ranks ninth14. 
 
MORTALITY 
 Colorectal cancer is the fourth most common cause of death from cancer 
worldwide15.  Survival is highly dependant on stage of the disease at diagnosis 
and ranges from 90% five years survival for cancers detected at the earlier 
stage, 70% in patients with regional metastasis and 10% in patients diagnosed 
with distant metastasis16,17.  
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ETIOLOGY AND RISK FACTORS 
 The risk factors can be classified as genetic, environmental, life style 
related factors. 
 
Genetic Factors 
 Colorectal carcinomas may or may not be associated with colonic 
polyposis. Colonic polyposis syndrome includes: 
 
- Familial adenomatous polyposis and its variants like Turcot syndrome, 
Gardner syndrome and attenuated FAP 
 
- Hereditary non polyposis colon cancer or Lynch syndrome comprises 
non-polyposis category. 
 
- Familial adenomatous polyposis is characterized by multiple colonic 
adenomatous polyps appearing in childhood with subsequent 
transformation to malignancy at an average age of 45 years and it is 
caused by genetic mutation in APC gene on chromosome 518. 
 
- Turcot syndrome- a variant of Familial adenomatous polyposis, 
associated with multiple colorectal adenomas and primary 
neuroepithelial brain tumors. 
 
Germline mutations of mismatch repair genes have been demonstrated. 
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Gardner syndrome- includes  mandibulomaxillary osteomas, multiple 
epidermoid cysts and multiple colonic polyps. 
 
- Attenuated FAP is associated with the same genetic mutation as in FAP, 
but is characterized fewer adenomas and later age of colorectal cancer 
presentation. 
 
- MYH-associated polyposis is inherited in an autosomal recessive 
pattern.  Mutations in the base excision repair gene mut Y homologue 
has been demonstrated. 
 
 
Hereditary Non-Polyposis Colon Cancer (Lynch syndrome):  
 
It is an autosomal dominant condition. Defects in any one of the 
following mismatch repair genes have been demonstrated- MLH 1, MSH 2, 
PMS 2 or  h MSH 6.   
 
ENVIRONMENTAL FACTORS: 
 Age – Old age has high risk 
 Gender – Colorectal cancer has a male preponderance19 
Inflammatory Bowel Disease – Both ulcerative colitis and Crohn’s 
disease can cause colorectal cancer20.   Extent of the disease, duration and 
activity are primary determinants21. People with Crohn’s disease have three 
times more risk of developing colorectal cancer compared to the general 
population22.  
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Ureterocolic anastomosis, long term immunosuppression23, following 
organ transplantation, insulin resistant Diabetes Mellitus (due to long-term 
effects of insulin-like growth factor)24,25,  pelvic irradiation26 increase the risk 
of colorectal carcinoma. 
 
LIFESTYLE RELATED FACTORS: 
 Consumption of fresh red meat and processed meat is associated with 
increased risk27,28,29. Alcohol consumption is a risk factor and reduction in 
alcohol consumption may reduce the incidence of colorectal cancer, especially 
in those with a positive family history30.  
 
 There is an inverse association with vegetable and fibre 
consumption31,32. Obesity33, cigarette smoking 34, sedentary lifestyle35, increase 
the risk. Folate ingestion reduces the risk36.  Use of NSAIDS, especially daily 
ingestion of low-dose aspirin decreases the incidence of colorectal cancer37.  
 
 COX-2 is overexpressed in 90% colorectal carcinomas and 40-90% 
adenomas. COX-2 is essential for prostaglandin E2 synthesis which in turn 
leads to epithelial proliferation, especially after epithelial injury. N-SAIDS 
inhibit COX-2, thereby reducing PGE-2 production and incidence of colorectal 
carcinoma38. 
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ANATOMY, EMBRYOLOGY & PHYSIOLOGY 
 It is necessary to study the difference between the segments of the large 
bowel to understand the mechanism of colorectal cancer. 
 
 The large intestine extends from the distal end of ileum to anus and 
measures about 1.5m; It consists of caecum, ascending colon, transverse colon, 
descending colon, sigmoid colon and rectum. 
 
 The junction between ascending colon and transverse colon is called 
hepatic flexure and the junction between transverse colon and descending 
flexure is known as splenic flexure. Rectum measures about 8-15 cm, lies in 
the pelvis and ends at the anal canal. 
 
 General characteristics of the large intestine are its large internal 
diameter compared to that of the small intestine and the presence of omental 
appendices which are peritoneum covered accumulations of fat. 
 
 The longitudinal muscle layer is segregated into 3 narrow bands called 
taeniae coli, which are prominent in the caecum and colon, less visible in the 
rectum. Haustrations represent the sacculations of the colon. Mucosa of the 
colon appears flat as there are no villi. Numerous non-branching crypts are 
seen punctuating the mucosa. 
 
 The proximal and distal colon are intraperitoneal whereas rectum is 
retroperitoneal. Proximal colon embryologically develops from the midgut, 
nourished by the branches of superior mesenteric artery, innervated by the 
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vagus nerve. The capillary network of the proximal colon are multilayered with 
increased capillary width in order to absorb water and electrolytes39,40.  
 
 Distal colon develops from the hindgut, nourished by the branches of 
inferior mesenteric artery, innervated by S2-S4 nerves. The capillary network is 
single-layered. Wall of the colon is thinner when compared to rectum when 
visualized by endoscopic ultrasonography with a higher average crypt length41. 
 
Histologically, the bowel wall consists of four layers namely mucosa, 
submucosa, muscularis proproia or muscularis externa and serosa. 
 
The mucosal surface is lined by a single layer of columnar cells. The 
surface epithelium is composed of absorptive cells and mucin secreting goblet 
cells. The epithelial cells rests on a thin basement membrane. 
 
The crypts of Lieberkuhn open directly on to the surface.  The crypts 
have a test-tube like shape and are arranged parallel to each other. 
 
Immunohistochemically, the epithelial cells of the normal colonic 
mucosa contain CK 18,CK 19, CK 20 but not CK 7. 
 
Lamina propria consists of collagen fibres, vessels, nerves, smooth 
muscle bundles, few lymphocytes, plasma cells and histiocytes. 
 
The submucosa contains loose connective tissue with vessels and 
nerves. Submucosal layer contains Meissner’s plexus of nerves. 
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Muscularis propria consists of inner circular and outer longitudinal 
layers. Auerbach’s myenteric plexus of nerves are present in between these two 
muscular layers. 
 
Serosa is composed of single layer of flattened mesothelial cells. Mucin 
secreting goblet cells are higher in rectum and sigmoid colon and there is a 
high concentration of endocrine cells in the rectum. In descending colon, 
neutral mucin is predominant, whereas in rectum acidic mucins predominate42. 
 
Sites of colorectal malignancies 
 Rectum and sigmoid colon are the most common sites for colorectal 
carcinomas. In recent years, there is an increase in the incidence of right sided 
colonic cancers. (arising proximal to splenic flexure)43,44.  
 
Females, past history of cholecystectomy, hormone therapy for prostate 
cancer, multiparity are some of the factors increasing the risk, possibly due to a 
change in metabolism of bile acids either in the component or quality. 
 
PATHOGENESIS OF COLORECTAL CARCINOMAS  
 Most colorectal carcinomas arise from adenomas45. Residual adenoma 
can be identified in about 10-30% cases while the remainder are overgrown and 
the precursor lesion is not apparent histologically46. Adenomas precede cancer 
by 15 years47. 
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ABERRANT CRYPT FOCI: 
 It is the earliest morphological precursor of epithelial neoplasia. 
Aberrant crypt foci have crypts of enlarged caliber and thickened epithelium 
with mucin depletion48. There are two subtypes: 
 
1) Hyperplastic type with RAS protooncogene mutation. 
2) Dysplastic type with APC gene mutation 
 
They represent the intermediate step between normal colonic epithelium 
and grossly apparent adenomatous growth49. 
 
Genetic Model: 
 Accumulation of genetic alterations leads to progression of adenoma to 
carcinoma50,51,52. 
 
Genome Instability: 
 It refers to increased acquisition and tolerance of mutation by the cells – 
which is a hallmark of colorectal cancer development53,54. 
 
 Genomic Instability is subdivided into: 
- Chromosome instability 
- Microsatellite instability –  
accounting for 85% and 15% colorectal carcinomas respectively. 
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APC was first identified as the gene mutated in FAP55. 
Sporadic colorectal cancers can also harbor APC mutation56. 
Thus APC is known as the gatekeeper gene of colorectal neoplasia. 
 
Other genetic alterations in colorectal carcinoma are the presence of 
activating KRAS mutations in about 35% of cases, leading to uncontrolled 
growth and reduced apoptosis57. Due to chromosomal deletions, TP53 
inactivation occurs is 50-70% cases58. 
 
ADENOMA-CARCINOMA SEQUENCE: 
 It accounts for 80% of sporadic colon tumors. 
 
Molecular basis for the evolution of colorectal cancer through the 
adenoma- carcinoma sequence. 
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APC-Beta-catenin pathway:  
Both mutation and epigenetic events like methylation induced gene 
silencing can cause functional inactivation of both copies of APC gene.  
 
APC is a negative regulator of beta-catenin, a component of WNT-
signaling pathway. The function of APC is to bind and cause degradation of 
beta-catenin. 
 
 With loss of APC function there is accumulation of beta-catenin which 
translocates to nucleus and causes transcription of genes encoding MYC and 
Cyclin D, thereby promoting proliferation.  
 
Thus, in APC/B-Catenin pathway, chromosomal instability is the 
hallmark. 
 
Microsatellite Instability: 
 Mutations accumulate in microsatellite repeats, in patients with DNA 
mismatch repair deficiency and this is referred to as microsatellite instability. 
When these mutations involve the coding / promoter region of the gene 
responsible for reputation of cell growth, uncontrolled cell growth occurs and 
increased survival of genetically abnormal clones ensures.  
 
BRAF mutations can also occurs. 
 
Combination of MSI, BRAF mutation and methylation of specific 
targets are the hallmark o this pathway59. The reference standard for large 
15 
 
intestinal cancers in a panel of 5 microsatellites (BAT 25, BAT 26, D5S346, 
D2S123, D17S250)60. 
 
 When instability occurs in any of the 2 microsatellites, it is called MSI-
H and if instability occurs in only one microsatellite it is called MSI-L. 
 
Genetic Susceptibility:  
Colorectal carcinomas can be associated with polyposis syndromes and 
non-polyposis syndromes. 
 
ADENOMATOUS POLYPOSIS SYNDROMES 
Familial Adenomatous Polyposis: 
 It is an autosomal dominant condition. Mutated APC gene can be 
inherited or new germline mutation of APC can occur61. Adenomas occur as a 
result of loss of second APC allele within colonic epithelial cells62. 
 
 FAP  is  defined  as  the  presence of >100 adenomatous polyps in the 
colon, many  patients  have  several  hundreds  to  thousands  of polyps. 
Adenocarcinomas occurs in mid-30s and as early as 17 years.  
 
FAP accounts for about 1% of colon cancers. There is equal sex 
predeliction and the frequency is about 1 in 8000 – 14000 in general 
population63. In FAP, COX2 inhibitors play a role in reducing polyp burden64.  
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Subtypes: 
 Gardner syndrome, Turcot syndrome, attenuated FAP. Treatment 
includes screening during adolescence and post adolescent prophylactic 
colectomy. 
 
Gardner’s Syndrome: 
 Patients with FAP who have manifestations in addition to those in GI 
tract are said to have Gardner’s syndrome65,66,67. 
 
 Clinical features include epidermal cysts, dental abnormalities, 
osteomas of mandible, skull and bony bones, aggressive desmoid tumors and 
congenital hypertrophy of retinal pigment epithelium. 
 
Turcot Syndrome: 
 It refers to the coexistence of hereditary colon cancer syndrome (FAP / 
HNPCC) and CNS Tumors68,69, most commonly medulloblastoma, astrocytoma 
and ependymoma. Distinct germline defects in either APC (in FAP) / DNA 
mismatch repair genes (in HNPCC). 
 
Attenuated FAP: 
 Polyps are less than 100 in number (usually <30)70,71. Adenomas and 
adenocarcinomas develop in later stages in life than in classic FAP. Lifetime 
risk of developing colonic malignancy is 80%. Flat adenomas are common.  
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HNPCC / Lynch  syndrome: 
 It has autosomal dominant mode of inheritance. 
 Inherited defects in atleast one of the family of DNA mismatch repair 
enzymes are present (hMLH, hMSH2, hMSH6, hPMS2)72,73 which leads to 
microsatellite instability and rapid accumulation of somatic mutations in genes 
that control tumor progression. Risk of developing colon cancer is 80-90%. 
 
Revised  Bethesda  guidelines  for  diagnosing  HNPCC  is  given  in      
annexure I. 
 HNPCC accounts for about 5% of all colonic cancers, with a 
predominance of right sided carcinomas at an early age. The tumors have 
signet-ring / mucinous component with a microglandular or medullary growth 
pattern with pushing margins. They are usually poorly differentiated with 
prominent tumor infiltrating lymphocytes. 
 
Juvenile polyposis syndrome:   
It is characterized by the presence of multiple juvenile polyps 
throughout the bowel. Juvenile polyps are also called retention polyps. 
Microscopically, juvenile polyps contain ulcerated surface with granulation 
tissue formation and underlying cystically dilated glands filled with mucus and 
separated by an edematous stroma. 
 
This condition is associated with development of multiple adenomatous 
polyps, leading to adenocarcinoma. 
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 Inactivating mutations of SMAD 4 have been demonstrated. 
 
Cronkhite – Canada syndrome: 
 It is a non- hereditary disorder characterized by multiple juvenile polyps 
associated with ectodermal changes. Adenomatous polyps and adenocarcinoma 
can develop. 
 
Peutz- Jeghers syndrome:  
It is characterized by the presence of Peutz – Jegher’s polyps. These 
polyps are defined by the presence of ramifying smooth muscle fibres from the 
muscularis mucosa, amomg the glands. 
 
 Germline mutations of LKB 1 gene have been demonstrated. This 
syndrome can be assoiated with adenomatous polyps with high grade dysplasia 
and adenocarcinoma of the large bowel. 
 
Cowden syndrome:  
It is an autosomal dominant condition, also known as multiple 
hamartoma syndrome . the polyps are characterized by disorganization and 
proliferation of the muscularis mucosa. 
 
Torre- Muir syndrome: 
 It is an autosomal dominant condition. Around 15% of females with this 
condition develop endometrial cancer and 50% of individuals with this 
syndrome develop colorectal carcinoma, most of which are found in the right 
colon. 
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NOTE: Any polyposis syndrome involving large intestine can evolve 
into a malignancy, FAP and Grdner syndrome having the greatest risk. 
 
GROSS APPEARANCE: 
 The gross appearance of colorectal carcinoma depends strongly on stage 
of the disease at diagnosis. ‘Small lesions’ may be sessile or pedunculated. 
‘Large’ carcinomas can be classified into 4 subtypes. 
 
1) Exophytic or polypoid tumors – rarely they cause obstruction and occur 
commonly in the caecum. 
 
2) Annular or constricting tumors – proximal fragment is dilated with 
flattened mucosa. It produces a ‘apple core appearance’ on radiography 
commonly causes functional obstruction. 
 
3) Infiltrative and ulcerating tumors – they are often raised, with irregular 
edges and central excavated area infiltrating into deep layers of bowel 
wall. 
 
4) Diffuse tumors – this subtype is similar to linitis plastica of stomach, 
with diffuse flattening and thickening of the colon. 
 
Cut section of the tumor appears homogenous admixed with areas of 
necrosis. Dilatation can occur as a result of obstruction and retraction of serosa 
occurs due to invasion of tumor into muscularis propria or subserosa. 
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MICROSCOPIC APPEARANCE: 
Criteria for malignancy: 
 Intramucosal adenocarcinoma refers to the malignancy confined to the 
lamina propria and muscularis mucosa. It is almost never associated with 
lymph node metastasis74 due to the relative paucity of lymphatics. Intramucosal 
carcinomas are denoted as Tis. Therefore, invasion into submucosa is required 
to call the colorectal carcinomas as T1. 
 
Diagnosis by Biopsy: 
 Endoscopic biopsies are used for diagnosis. To determine the presence 
of invasion is the most important aspect of pathological examination. WHO  
classification  of  tumors  of  colon  and  rectum  are  given  in annexure  II. 
 
Adenocarcinoma: 
 Colonic adenocarcinoma are usually moderately differentiated, the 
tumor cells being arranged as medium  to large sized glands with moderate 
variability in their size and configuration with a moderate amount of stroma. 
 
 Well differentiated tumors contain tall and columnar epithelial cells. The 
cells become polygonal or cuboidal with decreasing degrees of differentiation. 
Numerous mitotic figures are present. 
 
 Dirty Necrosis: 
 Refers to the presence of inspissated eosinophilic mucus, nuclear and 
cellular debris within the glandular lumen. Thus, when dirty necrosis is present 
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in a metastasis from an unknown primary, it is worth to search for a colorectal 
primary. 
 
 Leading edge of the tumor is usually associated with infiltrating glands. 
 
Desmoplastic reaction in the stroma can be prominent the presence of 
other cells in variable amounts, for example,  Paneth cells, neuroendocrine 
cells, squamous cells, trophoblasts are of no prognostic significance. 
 
Grading: 
 Grading is primarily based on the population  of the tumor cells that is 
composed of glands when compared to the areas with solid nests or cords of 
cells with lumina. Grading system endorsed by AJCC and WHO are used 
commonly74,75. 
 
 The tumors are graded according to the amount of differentiation. 
 
When >95% of the tumor cells are arranged as glands, they are said to 
be well differentiated.  
 
When <5% tumor cells are arranged as glands, they are called poorly 
differentiated tumors. 
 
 When there is no apparent gland formation; they are known as 
undifferentiated tumors.  
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According to this grading system, well, moderate and poorly 
differentiated tumors amount to 10%, 70%, and 20% cases respectively. 
 
The diagnosis of poorly differentiated adenocarcinoma has the highest 
rate of reproducibility and it is the one with a poor survival rate. 
 
Mucinous adeocarcinoma: 
 
 The term mucinous carcinoma refers to the tumors composed of >50% 
extracellular mucin. When the mucinous component is >10% or <50%, the 
tumors are referred to as adenocarcinoma with mucinous differentiation. 
 
Mucinous carcinomas contain strips of epithelial cells floating in 
extracellular pools of mucin and a variable member of signet ring cells may 
also be present. They constitute about 10% of all colonic cancers. They are 
common in patients with HNPCC and tend to present at a late stage. 
Microsatellite instability and defects in DNA mismatch repair are common. 76 
 
 Grossly, they are exophytic. Cut surface is soft and gelatinous. Paucity 
of fibrous tissue imparts a ‘colloid’ appearance to the cut surface. 
 
 Expression of HATH1, a transcription factor in activation of  MUC2 in 
colonic epithelium is a possible biologic basis for mucinous tumors. Mucinous 
carcinomas account for a greater proportion of right sided colonic tumors. 
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Microscopically, mucinous  adenocarcinomas have abundant large 
glandular structures embedded in extracellular pools of mucin. The mucin 
shows positive staining with Alcian blue or PAS stains.  
 
The tumor has infiltrative margins which contributes to the poor 
prognosis.77,78,79 
 
 They are more likely to develop peritoneal implants80 and a propensity 
to invade adjacent viscera81 and involve lymph nodes beyond the pericolonic 
region. 
 
Signet ring cell adenocarcinoma 
 
 They constitute about 0.5-1% of colorectal carcinomas and contains 
atleast 50% signet ring cells. They have a slight male preponderance and mean 
age of occurrence is 64 years.82 
 
 IBD is a risk factor for this tumor.83 They occur in equal frequency in 
right and left colon. Grossly, they are ulcerative. Microscopically, the tumor 
cells contain a characteristic mucin vacuole, which pushes the nuclei to the 
periphery of the cytoplasm. 
 
 The mucin in MUC-2 positive.84 The patients present at a later stage85. 
Peritoneal seeding is common 5 year survival rate is less than 10%. 
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Undifferentiated carcinomas 
 
 These tumors contain evidence of epithelial differentiation but there is 
no obvious gland formation there is less than 5% gland formation. 
 
 Grossly, they are bulky due to increased cellularity and soft due to lack 
of desmoplasia, contain extensive areas of necrosis. 
 
Microscopically, they have an infiltrating growth pattern. The tumor 
cells are arranged as sheets, cords and trabeculae with variable degrees of 
anaplasia. 
 
Medullary carcinoma 
 
 Also known as large cell minimally differentiated carcinomas86. It was 
first described by Gessures and co-workers87.  
 
The tumor cells have abundant cytoplasm, vesicular nuclei and 
prominent nucleoli and is associated with marked tumor infiltrating 
lymphocyte response. These tumors are common in women, caecum or 
proximal colon and associated with DNA mismatch repair. 
 
 They are negative for CK20 and positive for CK7. They have a 
favourable outcome. 
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Adenosquamous carcinoma 
 Constitute about 0.06% of all colorectal cancer. This tumor is associated 
with paraneoplastic hypercalcemia and PTH rP88,89. IBD is a risk factor 90,91. 
They occur in equal proportion is right and left colon. Overall 5 years survival 
rate is 3.1%92. 
 
Squamous Cell Carcinoma 
 It accounts of 0.1% of are colorectal cancer cases probable histogenesis 
is from a pluripotent stem cell 93,94 capable of multidirectional differentiation. 
HPV plays a role in pathogenesis95. 
 
Criteria for diagnosing primary SCC in colon 
- Exclusion of metastasis from other sites. 
- Extension from carcinoma of anus. 
- An associated squamous – lined fistulous tract must be excluded. 
 
Micropapillary carcinoma 
 It is an uncommon variant with a aggressive behavior. Microscopically, 
the neoplastic cells are arranged as balls or clusters and the cells have 
eosinophilic cytoplasm and vesicular nuclei. The tumor cells are surrounded by 
cleft-like spaces.  
 
The micropapillary component ranges from 5-80%. This variant is 
associated with a higher incidence of nodal and distant metastasis. 
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 The micropapillary pattern can be mistaken for tumor budding. But the 
tumor cell nests of micropapillary carcinoma are larger than that of 
budding96,97.  
 
Small Cell Variant 
 
 Constitutes <1% of all colorectal cancer.98 Microscopically they are 
similar to small cell carcinoma of lung. One third of these cases arise from 
typical adenomas. 
 
 Areas of squamous differentiation may be present. Expresses NSE, 
synaptophysin, chromagranin and has an extremely poor prognosis.  
 
Serrated Adenocarcinoma 
 
It refers to cancers arising from sessile serrated polyps or serrated 
adenomas.99 About 7.5% of all colon cancers are associated with serrated 
precursor lesions 100.  
 
Characteristic features of serrated carcinomas include serration of the 
glandular lining epithelium, cells with abundant eosinophilic cytoplasm and 
nuclei with peripheral condensation of chromatin. 
 
Subtypes include; 
- Proximal MSI-H cancers arising from sessile serrated polyps. 
- Distal MSI-H cancers arising from serrated adenomas. 
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Other Variants: 
 Carcinomas with spindle cell component are called sarcomatoid 
carcinoma. The spindle cells are immunoreactive for keratin.  
 
Carcinosarcoma refers to malignant tumors with both carcinomatous and 
heterologous mesenchymal elements.  
 
Rare hsitopathological variants of colorectal carcinoma includes 
pigmented, clear cell, pleomorphic, paneth cell rich variants. 
 
Colorectal cancer in patients younger than 40 years 
 
 It accounts for 1-2% of all colorectal cancers. A predisposing factor is 
present in about 21% of cases 101. The patients present at an advanced stage, 
most are <40 years and have regional or distant metastasis at the time of 
diagnosis. 102,103  
 
Common histological variants includes the mucinous adenocarcinoma 
and signet ring cell type tumors. Prognosis is poor in these cases. 
 
IMMUNOPHENOTYPE 
 
 It is used to differentiate between primary and secondary tumors and for 
the characterization of several subtypes. 
 
 CEA is the most commonly used stain to identify primary colonic 
cancer. 
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 CK-7 and CK-20 can also be used. 
 
 Villin is a protein that identifies intestinal differentiation.104 
 
CDX2, transcriptional factor is expressed in normal crypt epithelium 
and in 90% of colorectal adenocarcinomas 105,106. There is an immense 
relationship between tumor stage and CDX2 expression. 
 
MUC-2 is also a specific marker for colorectal carcinoma. 
 
COLORECTAL CANCER SCREENING:  
 
 It is done using a number of tests like stool examination for occult 
blood, colonoscopy, flexible sigmoidoscopy, radiological tests comprising of 
double contrast barium enema and CT colonography. 
 
 Screening for colorectal cancer is recommended for men and women 
more than 40 years of age as part of their routine annual check-up. 
 
PROGNOSIS: 
 5 year survival rate for colorectal carcinoma, after curative resection is 
40-60% 107,108,109. Two thirds of regional lymph node metastasis or local 
recurrences are evident within first 2 years110. 
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PROGNOSTIC FACTORS: 
 
Age: 
 Very young age and very old age are associated with poor prognosis.111 
 
Gender: 
 Females have better prognosis. 
 
Tumor location: 
 Tumors of left colon have a favourable outcome while those arising in 
sigmoid colon and rectum have a worse outcome112. 
 
Serum CEA levels: 
 Serum CEA levels >5ug/ml has a adverse effect on prognosis 113,114. 
 
Local Extent: 
 Microscopic carcinomas found incidentally in a polyps has excellent 
prognosis. Tumors extending beyond the bowel wall have worse prognosis. 
 
Tumor Size: 
Size of the tumor correlates with prognosis 115 and does not have any 
relation with metastasis to regional lymph nodes.116 
 
Tumor edge: 
 Tumors with non-polypoidal edges have worst prognosis.117,118 
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Obstruction: 
 Tumors presenting with destruction have a poor prognosis119,120. 
 
Perforation: 
 Extensive bowel wall infiltration by the tumor leads to perforation, 
which has got a poor prognosis121. 
 
Tumor Margins: 
 Carcinomas with pushing margins have a better prognosis.122,123 
 
Tumor budding:  
It is defined as the presence of isolated tumor cells or dusters of more 
than five cells at the invasive edge of the tumor, seen to migrate into the 
desmoplastic stroma.124 It has got a poor outcome.125,126 
 
Vascular invasion: 
 It is a sign of significant increase in incidence of distant metastasis. 
 Extramural venous invasion is an independent prognostic factor.127,128 
 
Angiogenesis: 
 Increased tumor angiogenesis predicts recurrence and is associated with 
reduced survival. Perineural invasion, when present is a poor prognostic sign. 
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Lymphnode involvement: 
 
 Adequacy of pathological examination is evaluated by the total number 
of lymph nodes sampled.129 Lymph node metastasis away from the primary 
tumor is usually associated with poor outcome. 
 
 Micrometastasis refers to solitary lymph node metastasis <2mm in 
size.130,131    
 
SPECIAL TECHNIQUES TO IMPROVE LYMPH NODE DISSECTION: 
Fat clearance methods:  
 Fat clearance methods of lymph node dissection by immersing the tissue 
in graded alcohol solutions can be used to increase the yield of lymph nodes. 
But, this method should be used only after complete assessment of the 
circumferential margins, the status of which is an extremely important 
prognostic factor. 
 
Sentinel lymph node examination: 
 They are the nodes which have the most direct drainage from the tumor. 
Therefore, meticulous examination of the sentinel lymph nodes can help in 
identifying patients who have primary tumor confined to the bowel wall and 
having unidentifiable metastasis at the time of surgical resection.  
 
 Sentinel lymph nodes are identified by injecting a blue dye in the 
subserosal layer. One to four lymph nodes that change color first are 
considered as sentinel lymph nodes. 
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   Host lymphatic response: 
 Various immunological and inflammatory reactions occur in response to 
colorectal cancer, including peritumoral lymphocytes, tumor infiltrating 
lymphocytes, reactive hyperplasia of regional lymph nodes etc.  
 
Crohn’s like lymphoid reaction in the peritumoral region can be graded 
as none, mild and marked. It is an independent prognostic factor.132,133 
 
 Tumor infiltrating lymphocytes are associated with colorectal cancers 
containing DNA mistmatch repair deficiency.134 5-7 IELS/HPF is the cut off  
and  it is a specific and sensitive marker for identification of MSI-H cancers. 
 
Microscopic tumor types:   
 Mucinous carcinoma, signet ring cell carcinoma are variants with poor 
prognosis. 
 
Staging: 
 Pathological staging is the most important factor determining the tumor 
behavior and patient outcome.135   
  
 AJCC  and  modified  Astler-Coller  staging are  given in  annexure  III. 
Pericolonic tumor deposits, when present is a poor prognostic factor.136 
 
Margin Status: 
 The presence of tumor in the radial margin is the most important factor 
in predicting local recurrence.137,138 
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Tumor thickness: 
 The thickness of tumor in the central depressed correlates with presence 
of lymph node and liver metastasis. 139 
 
Liver metastasis:   
About 15-25% cases have liver metastasis at the time of presentation; 
20% patients develop metastasis after treatment of primary tumor140. Without 
treatment, median survival after detection of liver metastasis is about 9 
months.141 
 
 In some patients, 5 year survival rates can be improved with resection of 
liver metastasis.142 
 
 After resection, the status of resected margins remains the most 
important prognostic factor. Patients with negative margins have a better 
outcome 143. Clearance of >1cm has a better outcome.144 
 
TARGETED THERAPY: 
The history of targeted therapy dates back to 1971, when Folkman 
hypothesized that administration of an agent that prevents angiogenesis can 
have dramatic effect on cancer treatment. 
 
 Targeted therapy is a type of chemotherapy which takes advantages of 
trivial differences between normal cells and cancer cells. The genetic and 
protein changes in cells causing cancer have been learnt through various 
researches. Newer drugs have been developed to target these changes. 
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 Their mechanism of action differs from that of standard chemotherapy 
drugs and often they have less adverse effects. They can also be used along 
with the standard chemotherapy regimes. 
 
 In colon cancer, monoclonal antibodies against VEGF and EGFR have 
been used for targeted therapies. 
 
 Bevacizumab is a well-known drug that inhibits angiogenesis. It was 
first approved based on its ability to improve survival in colorectal cancer 
patients. 
 
When used in conjunction with cytotoxic chemotherapy, it led to an 
additive suppression of tumor cell growth by enhancing apoptosis. 
 
Many other anti-angiogenesis agents like Valatinib, Afibercept are under 
trial.  
  
Many studies have been conducted based on the expression of VEGF in 
colorectal cancer. 
 
In a study conducted by Bendarafa R et al., in 360 colorectal cancer 
patients, cytoplasmic VEGF expression in the tumor cells was assessed by 
automated immunohistochemistry. Significant statistical association was found 
between VEGF expression and factors like location of the tumor (left sided 
tumors expressed VEGF more than the right sided tumors), stage of the disease 
and 10-year disease specific survival. Thus, assessing VEGF expression in 
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colorectal carcinoma helped in selecting patients who are likely to benefit from 
neoadjuvant chemotherapy. 
 
Zafirellis et al., did a study in 117 colorectal cancer patients and 
assessed the cytoplasmic VEGF expression in the tumor cells using semi-
automated computerized image analysis. Statistically significant association 
was found between presence of lymph node metastasis and stage of the disease. 
High levels of VEGF staining was seen to correlate with poor disease-specific 
survival (p<0.0001).  Thus, VEGF expression in colorectal cancer seems to be 
an independent prognostic factor and helps to identify patients with 
unfavourable clinical outcome. 
 
Yong-Song Guan et al., conducted a study in 71 colorectal cancer 
patients. VEGF expression by the tumor cells had statistically significant 
association with tumor stage, lymph node and liver metastasis and overall 
survival. 
 
Lee M. Ellis et al., performed a study in 52 colorectal cancer patients. 
VEGF expression correlated significantly with presence of lymphovascular 
invasion and lymph node metastasis. The patients who did not receive any 
adjuvant chemotherapy were followed up for 5 years and a direct correlation 
was present between VEGF expression and development of metastatic disease 
in colorectal cancer (p<0.0001) 
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Qingguo Li et al., conducted a study in 317 colorectal cancer patients. 
VEGF expression significantly correlated with tumor size, tumor stage, lymph 
node metastasis and distant metastasis. (p<0.05). the 5- year survival rate in  
patients with positive VEGF expression was 61.9%, whereas it was 70.2% in 
cases which did not express VEGF. 
  
VEGF 
Introduction: 
 
 It is a signal protein that stimulates vasculogenesis and angiogenesis145. 
It was discovered in 1983 by Sanger et al. 146 
 
Functions: 
 Its normal function is to create new blood vessels during embryonic 
development, after injury and to bypass blocked vessels. Solid cancers require 
adequate blood supply to grow beyond a limited size. Cancers expressing 
VEGF can grow and metastasize. 
 
Subtypes: 
 In mammals, VEGF comprises of five members, VEGF-A, Placental 
growth factor (PIGF), VEGF-B, VEGF-C & VEGF-D. 
 
Mechanism of action: 
 All the members of VEGF family act by binding to tyrosine kinase 
receptors on the cell surface. They are activated by transphosphorylation. The 
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hypoxic cells produce HIF (Hypoxia inducible factor) which stimulates the 
release of VEGF.  
 
VEGF receptors are classified into VEGF-R1, VEGF-R2, VEGF-R3. 
VEGF-R2 is located in vascular endothelial cells and VEGF-R3 on lymphatic 
endothelial cells and stimulate vasculogenesis and lymphangiogenesis 
respectively. Circulating VEGF binds to VEGFR on endothelial cells triggering 
tyrosine kinase pathway leading to angiogenesis. 
 
Anti-VEGF Therapy: 
 The first anti-VEGF drug Bevacizumab was approved in 2004. Many  
Anti-VEGF drugs are under trial. 
 
IMMUNOHISTOCHEMISTRY: 
 It is a method based on antigen-antibody reaction for localizing specific 
antigens in tissues or cells. 
 
In 1940, Coons detected antigens in frozen tissue sctions147. Taylor and 
Burns demonstrated antigens in FFPE tissues148. The antibody is labeled with 
an enzyme. Visualization of the labeled antibody by light microscopy is 
enabled by adding a suitable chromogen substrate. Greater sensitivity is 
obtained by using detection systems like Avidin-biotin complex, Peroxidase-
antiperoxidase, Biotin-Streptavidin method and polymer based labeling 
systems. 
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The technique if immunohistochemistry includes the following steps: 
- Preparation of  adhesive coated slides 
- Cutting of 4-5 micron sections 
- Deparaffinisation of the sections 
- Blocking the endogenous enzymes like peroxidase, alkaline 
phosphatase to avoid non-specific staining 
- Antigen retrieval to unmask the antigen 
- various methods can be used for antigen retrieval like use of the 
water bath, autoclaving, microwave heating or pressure cooker 
treatment. 
- The next step includes blocking of non-specific binding sites 
- Binding of primary antibody 
- Binding of secondary antibody 
- Use of detection methods like peroxidase - antiperoxidase, avidin – 
biotin conjugates, avidin – streptavidin complexes, polymer based 
detection systems. 
- Addition of chromogen substrate, usually DiAminoBenzidine(DAB) 
- Counterstaining, dehydrating and mounting the sections. 
 
Quality control in IHC: 
 Quality control measures should be taken care of during the pre-
analytical, analytical and post – analytical phases. 
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Use of controls:  
 
 Positive control tests the presence of antigen, integrity if the antibody 
and validates the methodology. The test is run on a tissue known to be 
immunoreactive for a particular primary antibody. It should have positive 
staining. 
 
 For the purpose of negative control, the same section used for positive 
control should be used. The primary antibody is replaced by a non-immune 
antiserum in the same dilution of the primary antibody. 
 
Recent advances in IHC: 
GENOGENIC IMMUNOHISTOCHEMISTRY: 
 It can be used to detect molecular changes by IHC. It can be used for 
diagnosis and therapy. With regard to colon cancer, microsatellite instability 
can be detected by genogenic immunohistochemistry. 
 
MONOCLONAL ANTIBODY DEVELOPMENT: 
 Development of highly specific antibodies using recombinant 
technology has paved way for the make of molecules with high stability, high 
potency and ultra-high affinity. 
 
AUTOMATION IN IMMUNOHISTOCHEMISTRY: 
 Automated techniques are available for the IHC procedure and also for 
microscopic image analysis. Computerised image capture and analysis systems 
are available. 
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MATERIALS AND METHODS 
 The study is based on colorectal adenocarcinomas. It is a combined 
prospective and retrospective study conducted in the Institute of Pathology, 
Madras Medical College, Chennai. It has been conducted over a period of 2 
years from July 2013 to July 2015. 
 
 We  received 147 cases of resected specimens of colorectal carcinomas 
for histopathological examination in our Institute of Pathology, during the 
period between July 2013 to July 2015. 
 
Inclusion Criteria: 
 Colorectal malignancies diagnosed  in resected specimens. 
 
Exclusion Criteria: 
 Small biopsies 
 Lymphoma of the colon  
 GIST  
 Non-neoplastic and benign lesions 
 
Method of data collection: 
 Relevant clinical details of the patients undergoing surgery for colorectal 
malignancy, regarding age, gender, procedure done were collected. 4um thick 
sections were taken from formalin fixed paraffin embedded tissue blocks and 
stained with hematoxylin and eosin. Among them, 50 random cases were 
selected for immunohistochemical studies. 
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 Immunohistochemical analysis was done using VEGF. 
 
Variables Studied: 
 The clinopathological variables studied were, age, gender, site of the 
tumor, procedure done, size of the tumor, gross appearance, histological type, 
grading and staging of the tumor, other prognostic factors like lymphovascular 
invasion and presence of lymph node metastasis. 
 
 Representation FFPE tissue samples were subjected to the with VEGF 
and immunoreactivity was analysed. 
 
Antigen Vendor 
Species 
(clone) 
Dilution 
Positive 
Control 
VEGF  Pathnsitu Mouse Ready to use 
Vascular 
endothelial 
cells 
 
Immunohistochemistry Procedure: 
 
Slide Preparation: 
 
 Sections with a thickness of 4-5u were cut from FFPE tissue and 
transferred to slides coated with gelatin and chrome alum. 
 
 The slides were incubated overnight at 58oC. The sections were 
deparaffinised in xylene for 30 minute (15 minute x 2 changes) 
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 The sections were dehydrated with absolute alcohol for 10 minutes (5 
minutes x 2 changes). The sections were then rinsed in distilled water for 5 
minutes. 
 
Antigen Retrieval 
 Retrieval buffer was prepared and was preheated for 4 minutes at 800W. 
  
The sections were then immersed in the retrieval buffer and incubated in 
the oven at 800W (5 minutes), 640W (5 minutes x 2 times) and 480W (5 
minutes). 
 
The slides were cooled at room temperature, washed with distilled water 
and then with TBS for 3 minutes (2 changes).  
 
Peroxidase block was applied over the sections for 10 minutes and then 
washed with TBS for 2 minutes (2 changes). 
 
Antibody Application: 
 The sections were treated with primary antibody for 30 minutes and 
washed with TBS for 2 minutes (2 changes). 
 
They were treated with polyexcel target binder for 15 minutes and 
washed with TBS for 2 minutes (2 changes). 
 
The sections were treated with HRP for 15 minutes and washed with 
TBS for 2 minutes (2 changes). 
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Chromogen Application: 
 
 DAB substrate was prepared by diluting 1 drop of DAB chromogen to 
1ml DAB buffer. DAB substrate solution was applied on the sections for 5 
minutes. 
 
 The slides were washed with distilled water for 2 minutes. 
 
The sections were counterstained with hematoxylin for 10 seconds. 
 
The slides were washed with distilled water for 5 minutes, air dried, 
cleared with xylene and mounted with DPX. 
 
Interpretation and scoring system: 
 
 The slides were analysed for the presence of immunohistochemical 
reaction, percentage of cells stained and intensity of the reaction. 
 
The slides were screened for cytoplasmic positivity of VEGF. Intensity 
of staining was classified as weak, moderate and strong. 
 
Scoring was done based on the proportion of the cells stained. 
 
 0 - no tumor cells show positivity 
 1 - <10 tumor cells show cytoplasmic positivity 
 2 - 11-50% cells show cytoplasmic positivity 
 3 - >50% cells show cytoplasmic positivity 
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Statistical analysis: 
 
 The statistical analysis was done using Statistical Package for Social 
Science software. The expression of VEGF was correlated with variables like 
age, gender, location, size, grade, stage, histological grade, lymph node 
involvement and lymphovascular invasion. 
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OBSERVATION AND RESULTS 
 
 From July 2013 to July 2015, we received 147 resected specimens of 
colorectal cancer for histopathological examination in the Institute of 
Pathology, Madras Medical College. 
 
Age distribution of the study participants: (Table 1, Fig. 1) 
 
 In this study the median age at presentation of colorectal cancer is 60 
years. The youngest age of presentation is 23 years and the oldest age of 
presentation is 79 years. Most of the cases were in the age range of 51 to 60 
years (42.9%). 
 
Table 1: Age distribution among the cases 
 
Age range Frequency Percent Valid 
Percent 
Cumulative 
Percent 
 
<30 
 
4 2.7 2.7 2.7 
31-40 
 
18 12.2 12.2 15.0 
41-50 
 
26 17.7 17.7 32.7 
51-60 
 
63 42.9 42.9 75.5 
61-70 24 16.3 16.3 91.8 
 
>70 12 8.2 8.2 100.0 
Total 147 100.0 100.0 
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Gender wise distribution of colorectal cancer: (Table 2, Fig. 2) 
 
In this study the incidence of colorectal cancer showed a male 
preponderance. Out of 147 cases 85 (57.8%) were males and 62 (42.2%) cases 
were females. 
 
Table 2: Gender distribution among the tumors 
Gender Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
Males 85 57.8 57.8 57.8 
 
Females 
 
62 
 
42.2 
 
42.2 
 
100.0 
Total 147 100.0 100.0 
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Site distribution of colorectal cancer: (Table 3, Fig.3) 
 
 Out of 147 cases, 104 (70.7%) cases occurred in left colon, 43 (29.3%) 
cases occurred in the right colon. Thus, in this study, left sided tumors were 
found to be  more  common than right sided tumors. 
 
Table 3: Distribution of side among the tumors 
Side Frequency Percent Valid Percent 
Cumulative 
Percent 
 
 
Right 
 
43 29.3 29.3 29.3 
Left 104 70.7 70.7 100.0 
Total 147 100.0 100.0 
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Distribution of colorectal cancer based on size: (Table 4, Fig. 4) 
 
 Out of 147 cases, the tumor was < 5cm in 79(54%) cases and >5cm in 
68(46%) cases 
 
Table 4: Distribution of size among the tumor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
size Frequency Percent 
 
>5 
 
68 46.3 
<5 
 
79 53.7 
Total 147 100.0 
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Distribution of colorectal cancer based on macroscopic appearance: 
(Table5, Fig 5) 
 
 Out of 147 cases. 92 (62.6%) cases were ulceroproliferative 23(15.6%) 
were ulcerative, 12 (8.2%) were ulceronodular, 14(9.5%) were circumferential. 
2 (1.4%) cases presented as stricture and 4 (2.7%) cases presented with 
polypoidal masses. 
 
Table 5: Distribution of gross features among the tumors 
Gross Frequency Percent Valid Percent 
Cumulative 
Percent 
Ulceroprliferative 92 62.6 62.6 62.6 
Ulcerative 23 15.6 15.6 78.2 
Ulceronodular 12 8.2 8.2 86.4 
Circumferential 14 9.5 9.5 95.9 
Stricture 2 1.4 1.4 97.3 
Polypoidal 4 2.7 2.7 100.0 
Total 147 100.0 100.0  
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Distribution of colorectal cancer based on histopathological  
subtypes : (Table 6, Fig. 6) 
 
 Among the 147 cases, 123 (83.7%) were infiltrating adenocarcinoma, 
6(4.1%) were infiltrating adenocarcinoma with mucinous differentiation 
14(9.5%) were mucinous carcinoma. 3(2%) were signet ring cell carcinoma, 
1(0.7%) was adeno carcinoma with neuroendocrine differentiation. 
 
Table 6: Distribution of microscopic types among the cases 
Microscopic subtype Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
 
Infiltrating 
adenocarcinoma 
 
123 83.7 83.7 83.7 
 
Adenocarcinoma with 
mucinous diff. 
6 4.1 4.1 87.8 
 
Mucinous carcinoma 14 9.5 9.5 97.3 
 
Signet ring cell 
carcinoma 
3 2.0 2.0 99.3 
 
Adeno ca with 
neuroendocrine diff. 
1 .7 .7 100.0 
 
Total 
 
147 100.0 100.0 
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Grade wise distribution of colorectal cancer: (Table 7, Fig. 7) 
 
 Out of 147 cases of colorectal cancer, 37(25.2%) well differentiated, 
95(64.6%) were moderately differentiated and 15(10.2%) were poorly 
differentiated. 
 
Table 7: Distribution of grade among the tumors 
 
Grade of 
differentiation 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Well 37 25.2 25.2 25.2 
Moderate 95 64.6 64.6 89.8 
Poor 15 10.2 10.2 100.0 
Total 147 100.0 100.0  
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Stage wise distribution of colorectal cancer: (Table 8, Fig 8) 
 
 Among 147 cases, 36 (24.5%) cases presented in stage B1, 44(29.9%) in 
B2, 14(9.5%) in C1 and 53 (36.1%) cases in C2. Most of the cases were in the 
stage C2.  
 
 
Table 8: Distribution of stage among the cases 
 
Stage Frequency Percent Valid 
Percent 
Cumulative 
Percent 
 
B1 36 24.5 24.5 24.5 
B2 44 29.9 29.9 54.4 
C1 14 9.5 9.5 63.9 
C2 53 36.1 36.1 100.0 
Total 147 100.0 100.0  
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Distribution of cases based on lymph node involvement: (Table 9, Fig.9) 
Among the 147 cases studied, 66(44.9%) had lymph node involvement and in 
81 (55.1%) cases, there was no involvement of lymph nodes. 
 
Table 9: Distribution of cases based on lymph node involvement 
Lymph node 
involvement 
Frequency Percent Valid Percent 
Cumulative 
Percent 
 
 
Absent 
 
81 55.1 55.1 55.1 
Present 
 
66 44.9 44.9 100.0 
Total 
 
147 100.0 100.0 
 
 
Distribution of other prognostic factors in colorectal cancer: 
 
 Out of the 147 cases, lymphatic invasion was present in 74 (50.3%) 
cases (Table 10, Fig.10), vascular invasion was present in 67 
(45.6%)cases(Table 11,Fig.11), lymphocytic response to the tumor was present 
in 76 (51.7%) cases(Table 12,Fig 12). Resected margins were free of tumor in 
143 (97.3%) cases(Table 13, Fig 13). 
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Table 10:  Distribution of lymphatic invasion among the cases 
 
Lymphatic         
invasion 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
Absent 73 49.7 49.7 49.7 
Present 74 50.3 50.3 100.0 
Total 147 100.0 100.0  
 
 
 
Table 11: Distribution of vascular invasion among the cases 
Vascular    
invasion 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
Absent 80 54.4 54.4 54.4 
Present 67 45.6 45.6 100.0 
Total 147 100.0 100.0  
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Table 12:  Distribution of lymphocytic response among the tumor 
 
Lymphocytic 
response 
Frequency Percent Valid Percent 
Cumulative 
Percent 
 
Absent 71 48.3 48.3 48.3 
Present 76 51.7 51.7 100.0 
Total 147 100.0 100.0  
 
 
 
 
Table 13: Margin status of the tumors 
 
 
Margin status Frequency Percent Valid Percent Cumulative 
Percent 
 
Free 143 97.3 97.3 97.3 
Involved 4 2.7 2.7 100.0 
Total 147 100.0 100.0 
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RESULTS OF IMMUNOHISTOCHEMICAL ANALYSIS: 
 
Out of the 147 cases, 50 random cases were selected and subjected to 
immunohistochemical analysis for VEGF expression. 
 
Among the 50 cases, 9 cases(18%) showed cytoplasmic VEGF 
expression in   <10 % of tumor cells(1+), 20 cases(40%) showed positivity in 
10-50% tumor cells(2+)  and 21 cases(42%) expressed cytoplasmic VEGF in 
>50% tumor cells(3+).(Table14, Fig. 14) 
 
 
Table 14:  Distribution of varying levels of VEGF 
expression among the cases 
 
VEGF    
expression Frequency Percent Valid Percent 
Cumulative 
Percent 
 
 
1+ 
 
9 18.0 18.0 18.0 
2+ 
 
20 40.0 40.0 58.0 
3+ 
 
 
21 42.0 42.0 100.0 
Total 50 100.0 100.0 
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CORRELATION OF VEGF EXPRESSION WITH VARIOUS 
CLINICOPATHOLOGICAL PARAMETERS: 
AGE: 
Among the 50 cases chosen, youngest and oldest ages were 28 and 79 
years respectively. Median age for 1+, 2+ and 3+ VEGF expression were 57, 
57 and 59 years respectively. The association between VEGF expression and 
age is statistically insignificant. (Table 15, Fig.15) 
 
Table 15: Correlation of age and VEGF expression 
Correlation of 
age and VEGF 
expression 
Mean Median Minimum Maximum 
Standard 
Deviation 
Standard 
Error of 
Mean 
VEGF 
 
1+ 
AGE 57.56 57.00 47.00 65.00 6.56 2.19 
 
2+ 
AGE 57.15 57.00 28.00 79.00 13.98 3.13 
3+ AGE 59.10 59.00 33.00 78.00 11.32 2.47 
 
GENDER:  
Among the 50 cases, 25 were males and 25 were females. Out of the 25 
males 1+, 2+ and 3+ VEGF expression were found in 4,9 and 12 patients 
respectively. 
58 
 
Among the 25 females, 1+, 2+ and 3+ VEGF expression were found in 
5,11 and 9 cases respectively. The association between gender and VEGF 
expression is statistically insignificant.( Table 16) 
 
Table 16: Correlation between gender and VEGF expression 
Correlation  between gender 
and VEGF expression 
VEGF 
Total 
1+ 2+ 3+ 
Gender 
Male 
Count 4 9 12 25 
% within 
VEGF 
44.4% 45.0% 57.1% 50.0% 
Female 
 
Count 5 11 9 25 
% within 
VEGF 
55.6% 55.0% 42.9% 50.0% 
Total 
Count 9 20 21 50 
% within 
VEGF 
100.0% 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=.740  p>0.05(0.691) 
 
LOCATION:  
Out of the 50 cases chosen 14 were right sided tumors and 36 were left 
sided tumors. Among the right sided tumors, 1+,2+ and 3+ VEGF expression 
was found in 4,7 and 3 cases respectively. Out of the 36 left sided tumors , 1+, 
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2+ and 3+ VEGF expression were found  in 5,13 and 18 cases 
respectively(Table 17). The association between VEGF expression and location 
of the tumor is statistically insignificant. 
 
Table 17: Correlation between location of the tumor and VEGF 
expression 
 
Correlation between VEGF 
expression and location of 
the tumor 
VEGF 
 Total 
1+ 2+ 3+ 
 
Right 
 
 
 
Count 4 7 3 14 
% within 
VEGF 
44.4% 35.0% 14.3% 28.0% 
 
Left 
Count 5 13 18 36 
% within 
VEGF 
 
55.6% 65.0% 85.7% 72.0% 
Total 
Cont 9 20 21 50 
% within 
VEGF 
100.0% 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=3.653  p>0.05(0.161) 
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SIZE:   
Of the 50 cases chosen, 25  were less than 5 cm and 25 were more than 
5 cm in greatest dimension(Table18). The association between VEGF 
expression and size of the tumor is statistically insignificant. 
 
Table 18: Correlation between tumor size and VEGF expression 
Correlation between size of the 
tumor and VEGF expression 
 
VEGF 
 Total 
1+ 2+ 3+ 
SIZE 
<5 cm 
Count 3 13 9 25 
% within 
VEGF 
 
33.3% 65.0% 42.9% 50.0% 
>5 cm 
Count 6 7 12 25 
% within 
VEGF 
66.7% 35.0% 57.1% 50.0% 
Total 
 
Count 
 
9 20 21 50 
% within 
VEGF 
 
100.0% 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=3.229  p>0.05 (0.199) 
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GRADE:  
Among the 50 cases, 16 were well differentiated, 29 were moderately 
differentiated and 5 were poorly differentiated. The varying levels of VEGF 
expression by these tumors is shown in Table  19 . The association between 
VEGF expression and grade of the tumor is statistically insignificant. 
 
 
 
Pearson Chi-Square=4.467  p>0.05(0.347) 
Table 19: Correlation between VEGF expression and grade of the tumor 
Correlation between VEGF 
expression and grade of the 
tumor 
VEGF 
 
Total 
1+ 2+ 3+ 
 
Well 
Count 2 7 7 16 
% within 
VEGF 
 
22.2% 35.0% 33.3% 32.0% 
Moderate 
Count 7 12 10 29 
% within 
VEGF 
77.8% 60.0% 47.6% 58.0% 
Poor 
Count 
 
0 1 4 5 
% within 
VEGF 
0.0% 5.0% 19.0% 10.0% 
Total 
Count 9 20 21 50 
% within 
VEGF 
 
100.0% 100.0% 100.0% 100.0% 
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LYMPHATIC INVASION:  
Out of the 50 cases, 35 cases had lymphatic invasion and 2,14 ,19 cases 
had 1+,2+,3+ VEGF expression respectively(Table20,Fig 16). The association 
between VEGF expression and presence of lymphatic invasion proved to be 
statistically significant. 
 
Table 20 : Correlation between VEGF expression and 
presence of lymphatic invasion 
Correlation between VEGF 
expression and lymphatic 
invasion 
VEGF 
 Total 
1+ 2+ 3+ 
 
Absent 
 
Count 7 6 2 15 
% within 
VEGF 
77.8% 30.0% 9.5% 30.0% 
Present 
Count 2 14 19 35 
% within 
VEGF 
22.2% 70.0% 90.5% 70.0% 
Total 
Count 9 20 21 50 
% within 
VEGF 
100.0% 100.0% 100.0% 100.0% 
 
      p<0.05 
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VASCULAR INVASION:  
Among the 50 cases, 35 cases had vascular invasion and 3,15,17 cases 
had 1+,2+,3+ VEGF expression respectively(Table 21, Fig 17). The association 
between VEGF expression and presence of vascular invasion proved to be 
statistically significant. 
 
Table 21: Correlation between VEGF expression and presence  
of  vascular invasion 
Vascular 
invasion 
VEGF 
1+ 2+ 3+ TOTAL 
Absent 6 5 4 15 
% 67% 25% 19% 30% 
Present 3 15 17 35 
% 33% 75% 81% 70% 
Total 9 20 21 50 
18% 40% 42% 
CHI SQUARE 7.20 p value = 0.027 
 
LYMPH NODE METASTASIS:  
Out of the 50 cases, 27 patients had metastasis to the regional lymph 
nodes; 1,10,16 cases had 1+,2+,3+ VEGF expression respectively(Table 22, 
Fig 18). The association between VEGF expression and presence of lymph 
node metastasis is statistically significant. 
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Table 22: Correlation  between VEGF expression and lymph 
node involvement 
 
Correlation between VEGF 
expression and lymph node 
involvement 
VEGF 
Total 
1+ 2+ 3+ 
 
Absent  
Count 8 10 5 23 
% within 
VEGF 
88.9% 50.0% 23.8% 46.0% 
Present  
Count 1 10 16 27 
% within 
VEGF 
11.1% 50.0% 76.2% 54.0% 
Total 
Count 9 20 21 50 
% within 
VEGF 
100.0% 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=10.956*  p<0.05 significant 
 
STAGE:   
Among the 50 cases chosen, 5,18,8,19 cases belonged Astler-Coller 
stage B1,B2,C1,C2 respectively(Table 23, Fig 19). Varying levels of VEGF 
expression in these tumors is given in Table The association between VEGF 
expression and stage of the tumor is found to be statistically significant. 
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Table 23: Correlation between VEGF expression and  
stage of the tumor 
Correlation between 
VEGF expression and 
stage 
VEGF Total 
1+ 2+ 3+ 
Stage 
B1 
Count 3 1 1 5 
% within 
VEGF 
33.3% 5.0% 4.8% 10.0% 
 
B2 
Count 5 9 4 18 
% within 
VEGF 
55.6% 45.0% 19.0% 36.0% 
 
C1 
Count 1 5 2 8 
% within 
VEGF 
11.1% 25.0% 9.5% 16.0% 
 
C2 
Count 0 5 14 19 
% within 
VEGF 
0.0% 25.0% 66.7% 38.0% 
 
Total 
Count 9 20 21 50 
% within 
VEGF 
100.0% 100.0% 100.0% 100.0% 
 
    Pearson Chi-Square=19.607*  p<0.05 significant 
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The overall clinicopathological profile is given in Table 24. 
 
  
Clinico-pathological factor No. of cases (%) 
 
Age 
<50 years 48(32.7%) 
>50 years 99(67.3%) 
Histological 
type 
Infiltrating adenocarcinoma 123(83.7%) 
Infiltrating adenocarcinoma 
with mucinous 
differentiation 
6(4.1%) 
Mucinous adenocarcinoma 14(9.5%) 
Signet ring cell 
adenocarcinoma 
3(2%) 
 Infiltrating adenocarcinoma 
with neuroendocrine 
differentiation 
1(0.7%) 
Grade of 
differentiation 
Well 37(25.2%) 
Moderate 95(64.6%) 
Poor 15(10.2%) 
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Clinico-pathological factor No. of cases (%) 
Stage B1 36(24.5%) 
B2 44(29.9%) 
C1 14(9.5%) 
C2 53(36.1%) 
 
Lymph node 
Positive 66(44.9%) 
Negative 81(55.1%) 
 
Tumor Size 
<=5 cm 79(54%) 
>5 cm 68(46%) 
VEGF 
expression 
1+ 9(18%) 
2+ 20(40%) 
3+ 21(42%) 
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DISCUSSION 
 
Globally, colorectal cancer poses a major public health problem. It is the 
fourth most common cause of death from cancer, worldwide. In India, cancer 
of the colon ranks among the top ten in men and women. 
 
Survival is mainly dependant on the stage of the disease at diagnosis; 
with a better 5-year survival for patients diagnosed at the localized stage. Many 
biological markers are being studied, in order to explore their prognostic 
significance.  
 
In this study, Immunohistochemical evaluation is done in 50 cases of 
colorectal carcinoma and is correlated with various clinicopathological 
parameters. 
 
The median age of presentation of colorectal carcinoma is 60 years; the 
youngest and oldest ages of presentation being 23 and 79 years respectively.  
 
COMPARISON WITH OTHER STUDIES MEDIAN AGE 
 
Table 25 : Comparison of median age with other studies 
 
Studies 
Troisi et 
al.150 
Robin.P.Burshey  
et al.151 
Chu KC 
et al.152 
Gendi 
et al153 
Current 
study 
Median 
age (yrs) 
60 72 58 55 60 
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The median age of occurrence of colorectal carcinoma is compared with 
other studies.  
 
Troisi et al. conducted a study in 223 colorectal carcinoma patients and 
found that the mean age at diagnosis was  60 years. 
 
Robin. P.Burshey et al. conducted a study in 168 colorectal carcinoma 
patients and concluded that the median age at diagnosis was 72 years.  
 
Chu KC et al. and Gendi et al conducted studies in 108 and 159 
colorectal carcinoma patients and found that the median age at diagnosis was 
58 and 55 years respectively. 
 
The median age at diagnosis of colorectal carcinoma in this study is 60 
years which is in concurrence with the stuby done by Troisi et al. (Table 25) 
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LOCATION OF THE TUMOR 
 
Table 26: Comparison of tumor location with other studies 
 
Tumor location Left side Right side 
Troisi et al150 52.5% 47.5% 
Kazem et al 155 56.7% 43.3% 
N.Scott et al 154 69.2% 30.8% 
Gendi et al153 75% 25% 
Current study 70.7% 29.3% 
     
In a study conducted by Kazem et al. and Scott et al ,left sided tumors 
constituted about 56.7%, 69.2% and right sided constituted about 43.3%,308% 
respectively. 
 
In the current study, left  and right sided tumors constitute about 70.7% 
and 29.3% respectively, which is in concurrence with the study conducted by 
Gendi et al ., in which left sided tumors were about 75% and right sided tumors 
were about 25% (Table 26). 
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HISTOLOGICAL TYPES 
 
Table 27: Comparison of histological subtype of colorectal  
carcinoma with another study 
 
Histological type Kazem et al159 Current Study 
Infiltrating Adenocarcinoma 86.7% 83.7% 
Infiltrating Adenocarcinoma With 
Mucinous Differentiation 
- 4.1% 
Signet Ring Cell Carcinoma 3.3% 2% 
Mucinous Adenocarcinoma 10% 19.5% 
Adenocarcinoma with neuroendocrine 
differentiation 
- 0.7% 
 
In the study conducted by Kazem et al. in 323 colorectal carcinoma 
patients, the most common microscopic subtype was infiltrating 
adenocarcinoma which constituted about 86.7%, followed by mucinous 
carcinoma which was about 10% The main histolopathological subtype of 
colorectal carcinoma in this study is Infiltrating adenocarcinoma which is in 
concurrence with the study of Kazem et al. (Table 27) 
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COMPARISON OF EXPRESSION OF VASCULAR ENDOTHELIAL 
GROWTH FACTOR AND CLINICOPATHOLOGICAL 
CORRELATION IN COLORECTAL CARCINOMA WITH OTHER 
STUDIES: 
 
Association between presence of lymphatic and vascular invasion and 
VEGF expression: 
 
In the current study, the association between VEGF expression and the 
presence of lymphovascular invasion is clinically significant. This is in 
concurrence with many studies conducted elsewhere. (Table 28) 
 
Table 28: Comparison of VEGF expression and presence of 
lymphovascular invasion with other studies 
 
Studies 
No. of cases 
studied 
p Value for lymphovascular 
invasion and VEGF expression 
Yukata et al. 52 0.03 
Kang SM et al 156 0.004 
Tucker et al. 27 0.014 
Current study 50 0.027 
 
In a study conducted by Yukata et al in 52 colorectal carcinoma patients, 
significant statistical association was found between presence of 
lymphovascular invasion and lymph node involvement. Also in studies 
conducted by Kang SM et al. and Tucker et al. in 156 and 27 patients 
respectively, there was a significant association between VEGF expression and 
presence of lymphatic and vascular invasion. 
73 
 
 
Table 29: Comparison of VEGF expression and presence of lymph node 
involvement with other studies 
 
Association between VEGF expression and lymph node involvement: 
In this study, there is a significant association( p value<0.05) between 
presence of lymph node metastasis and level of VEGF expression.(Table 29). 
In studies conducted by Martius et al., Yeb CY et al., Wang D et al., and Lee 
JC et al. in 672, 58, 317 and 92 colorectal carcinoma patients respectively, 
there is significant association between VEGF expression and lymph node 
involvement 
  
Studies 
No. of patients 
studied 
p value for lymph node involvement 
and VEGF expression 
Martius et al159 672 0.03 
Yeb CYet al160 58 0.042 
Wang D et al161 317 0.039 
Lee JC et al162 92 0.042 
Current study 50 0.04 
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Association between stage of the disease and VEGF expression:    
 In this study, there is a significant association between staging of the 
tumor and levels of VEGF expression.  Tumors belonging to Astler-Coller 
stage C2 had expressed more VEGF when compared to others. (Table 30) 
 
Table 30: Comparison of VEGF expression and tumor stage   
with other studies 
Studies No. of cases studied 
p Value for stage of the 
disease and VEGF 
expression 
Bendarafa et al163 360 0.04 
Okita et al164 91 0.032 
Ochs et al165 109 0.04 
Zafirellis et al166 117 0.026 
Current study 50 0.038 
 
 Also in studies conducted by Okita et al., Bendarafa et al., Ochs et al., 
Zafirellis et al., in 91, 360, 109 and 117 colorectal carcinoma patients, 
significant statistical association was found between VEGF expression and 
stage of the tumor. 
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CORRELATION BETWEEN TUMOR DIFFERENTIATION AND 
VEGF EXPRESSION: 
 
Table 31: comparison of VEGF expression and tumor  
differentiation with other studies 
Studies 
Tumor 
differention 
VEGF 1+ VEGF 2+ VEGF 3+ p value 
Shu Zheng 
et al. 
Well 
Moderate 
Poor 
10 
5 
3 
6 
11 
9 
12 
20 
21 
 
0.028 
Current  
study 
Well 
Moderate 
Poor 
2 
7 
0 
7 
12 
1 
7 
10 
4 
 
0.34 
 
In the current study, 16 cases were well differentiated tumors. Out of the 
16 cases, 1+, 2+ and 3+ VEGF expression was found in 2,7 and 7 cases 
respectively. There were 29 moderately differentiated tumors, among which 
1+, 2+ and 3+ VEGF expression were found in 7, 12 and 10 cases respectively. 
Out of the 5 poorly differentiated tumors, 1+, 2+ and 3+ VEGF expression 
were found in 0,1 and 4 cases respectively. There is no significant association 
between grade of the tumor and VEGF expression. 
In a study conducted by Shu Zheng et al., in 97 colorectal cancer 
patients, there was a significant statistical association between VEGF 
expression and grade of the tumor. 
Qingguo et al., conducted a study in 317 colorectal cancer patients, there 
was no significant association between VEGF expression and tumor 
differentiation. 
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SUMMARY 
 
 From July 2013 to July 2015, 147 resected specimens of colorectal 
cancer were received for histopathological examination in Institute of 
Pathology, Madras Medical College. 
 
• The median age at presentation is 60 years 
• Youngest age of presentation is 23 years 
• Oldest age of presentation is 79 years 
• Maximum number of cases occurred in the age group of 50-60 years 
• There is a male preponderance -85 cases(57.8%) 
• Left sided tumors are more common-104 cases(70.7%) 
• 54% cases had tumors less than 5 cm in greatest dimension 
• Commonest gross appearance is ulceroproliferative -92 cases(62.6%) 
followed by the ulcerative type-23 cases(15.6%) 
• Most common histopathological subtype is Infiltrating adenocarcinoma-
123 cases(83.7%). 
• Commonest grade is moderately differentiated-95 cases(64.6%) 
• 53 cases(36.1%) belonged to Astler-Coller stage C2. 
• 66 cases(44.9%) had lymph node involvement 
• 74 cases(50.3%) had lymphatic invasion 
• 67 cases(45.6%) had vascular invasion 
• 76 cases(51.7%) had tumor infiltrating lymphocytes 
• Resected margins were free in 147(97.3%) cases 
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• Out of 147 cases, immunohistochemical analysis was done for 
expression of VEGF in 50 random cases. 
• 9(18%), 20(40%) and 21(42%) cases had 1+,2+ and 3+ levels of VEGF 
expression respectively 
• There is no significant association between VEGF expression and 
factors like age, gender, location, size and grade of the tumor 
• Statistically significant association is present between VEGF expression 
and factors like presence of lymphatic invasion, vascular invasion, 
lymph node metastasis and stage of the tumor. 
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CONCLUSION 
 
 Among the 147 cases studied at the Institute of Pathology, Madras 
Medical College from July 2013-July 2015, median age at presentation is 60 
years, with a male preponderance. Left sided tumors are common; Infiltrating 
adenocarcinoma with  moderate differentiation being the predominant 
histopathological subtype. 
   
Immunohistochemical analysis was performed to assess the expression 
of Vascular Endothelial Growth Factor by the tumor cells in 50 cases. 
Significant association was found between VEGF expression and stage of the 
tumor, presence of lymphatic invasion, vascular invasion and lymph node 
metastasis. 
   
This study throws light on the need for targeted therapy with anti- 
VEGF drugs to minimize pathological vasculogenesis in the tumor, occurrence 
of  regional and distant metastasis, thereby improving patient survival. 
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 ANNEXURE I 
 
                 Bethesda Guidelines for HNPCC (Revised) 
 
1. Colorectal cancer diagnosed before age 50 years 
2. Multiple colorectal cancer or HNPCC-related cancersa 
3. Colorectal cancer with MSI-related histologyb diagnosed before age 60 
years 
4. Colorectal cancer or HNPCC-related cancer diagnosed in at least one 
first-degree relative before age 50 years 
5. Colorectal cancer or HNPCC-related cancer diagnosed in at least two 
first- or second-degree relatives at any age 
Any criterion (1 to 5) can be met. 
HNPCC, hereditary nonpolyposis colorectal cancer; MSI, microsatellite 
instability. 
a Includes cancer of endometrium, small bowel, pelvis/ureter, biliary tract, 
stomach, ovary, pancreas, or brain (mainly glioblastoma multiforme). 
 
b Includes tumor-infiltrating lymphocytes, Crohn-like lymphocytic reaction, 
mucin/signet ring cell differentiation, and medullary growth pattern. 
 
 
  
ANNEXURE II 
 
WHO histological classification of tumours of the colon and rectum 
 
Epithelial tumours 
Adenoma  
Tubular  
Villous  
Tubulovillous  
Serrated  
 
Intraepithelial neoplasia (dysplasia) 
associated with chronic inflammatory diseases 
Low-grade glandular intraepithelial neoplasia 
High-grade glandular intraepithelial neoplasia 
 
Carcinoma 
Adenocarcinoma  
Mucinous adenocarcinoma  
Signet-ring cell carcinoma  
Small cell carcinoma  
Squamous cell carcinoma  
Adenosquamous carcinoma  
Medullary carcinoma  
Undifferentiated carcinoma  
Carcinoid (well differentiated endocrine neoplasm)  
EC-cell, serotonin-producing neoplasm  
L-cell, glucagon-like peptide and PP/PYY producing tumour 
Others 
 
Mixed carcinoid-adenocarcinoma  
Others 
 
Non-epithelial tumours 
Lipoma  
Leiomyoma  
Gastrointestinal stromal tumour  
Leiomyosarcoma  
Angiosarcoma  
Kaposi sarcoma  
Malignant melanoma  
Others 
Malignant lymphomas 
Marginal zone B-cell lymphoma of MALT Type  
Mantle cell lymphoma 
Diffuse large B-cell lymphoma  
Burkitt lymphoma  
Burkitt-like /atypical Burkitt-lymphoma  
Others 
Secondary tumours 
Polyps 
Hyperplastic (metaplastic) 
Peutz-Jeghers 
Juvenile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE III 
 
 American Joint Committee on Cancer Staging for Colorectal Cancer 
American Joint Committee 
on Cancer 
Dukes 
Staging 
Modified Astler-Coller 
Classification 
Stage 0: Tis, N0, M0 A A 
Stage I: T1, N0, M0 or T2, N0, 
M0 
A A/B1 
Stage IIA: T3, N0, M0 B B2 
Stage IIB: T4, N0, M0 B B2 
Stage IIIA: T1-2, N1, M0 C C1 
Stage IIIB: T3-4, N1, M0 C C2 
Stage IIIC: T any, N2, M0 C C1/C2 
Stage IV: T any, N any, M1 D D 
 
 
          Tis, carcinoma in situ; T1, tumor invades into submucosa; T2, tumor 
invades into muscularis propria; T3, tumor invades through the muscularis 
propria into the subserosa or into nonperitonealized pericolonic or perirectal 
tissue; T4, tumor perforates the visceral peritoneum or invades directly into 
other organs or tissues; N0, no lymph node metastases; N1, metastatic tumor in 
one to three pericolic or perirectal lymph nodes; N2, metastatic tumor in four or 
more pericolic or perirectal lymph nodes; N3, metastases in any lymph node 
along the course of a major named blood vessel; M0, no distant metastases; 
M1, distant metastases present. 
 
 
KEY TO MASTER CHART 
 
GENDER 
 1-MALE 
 2-FEMALE 
 
P/D-PROCEDURE DONE 
 1-RIGHT HEMICOLECTOMY 
 2-LEFT HEMICOLECTOMY 
 3-ABDOMINOPERINEAL RESECTION 
 4-ANTERIOR RESECTION 
 5-ULTRA LOW ANTERIOR RESECTION 
 6- SIGMOIDECTOMY 
 7-PELVIC EXENTRATION 
 8-SUBTOTAL COLECTOMY 
 9-TOTAL PROCTOCOLECTOMY 
 10-HARTMANN’S PROCEDURE 
 
LOCATION 
 1-RIGHT 
 2-LEFT 
 
GROSS APPEARANCE 
 1-ULCEROPROLIFERATIVE 
 2-ULCERATIVE 
 3-ULCERONODULAR 
 4-CIRCUMFERENTIAL 
 5-STRICTURE 
 6-POLYPOIDAL 
 
HPE-HISTOPATHOLOGICAL EXAMINATION 
 1-INFILTRATING ADENOCARCINOMA 
2-INFILTRATING ADENOCARCINOMA WITH MUCINOUS  
    DIFFERENTIATION 
3-MUCINOUS CARCINOMA 
4-SIGNET RING CELL CARCINOMA 
5-INFILTRATING ADENOCARCINOMA WITH  
    NEUROENDOCRINE DIFFERENTIATION 
 
GRADE 
 1-WELL DIFFERENTIATED 
 2-MODERATELY DIFFERENTIATED 
 3-POORLY DIFFERENTIATED 
 
LN METS-LYMPH NODE INVOLVEMENT 
 Y-PRESENT 
 N-ABSENT 
 
LI-LYMPHATIC INVASION 
 Y-PRESENT 
 N-ABSENT 
 
VI-VASCULAR INVASION 
 Y-PRESENT 
 N-ABSENT 
 
 
LCI-LYMPHOCYTIC INFILTRATION 
 Y-PRESENT 
 N-ABSENT 
 
MAC- MODIFIED ASTLER-COLLER STAGE 
MARGINS 
 1-FREE  
 2-INVOLVED 
 
VEGF EXPRESSION 
 1+  <10% CELLS SHOW CYTOPLASMIC POSITIVITY 
 2+  10-50% CELLS SHOW CYTOPLASMIC POSITIVITY 
 3+  >50% CELLS SHOW CYTOPLASMIC POSITIVITY 
 
  
 
 
 
 
MASTER CHART 
 
S.No HPE No Age Gender Location P/D Size Gross HPE Grade LCI LI VI LN Mets MAC Margins VEGF
1 2906/13 61 1 2 10 3.5*2*1 1 1 1 N N N N 2 1
2 2931/13 49 2 2 4 4*4*1.5 1 1 2 N N N N 1 1
3 3959/13 60 1 2 10 3*2*1 1 1 2 N Y Y Y 4 1
4 4634/13 55 2 2 10 5*3*3 3 2 3 N Y Y Y 4 1
5 4644/13 55 2 2 10 2*1*0.5 2 1 2 Y N N N 3 1
6 5056/13 65 2 2 6 4*3.5*1.5 1 1 2 Y Y Y Y 3 1
7 5078/13 46 1 2 3 2*2*1.5 1 1 2 Y N N N 1 1
8 5347/13 60 1 2 10 6*5*4 1 3 2 N N N N 1 1
9 5582/13 36 1 2 6 3*2*0.5 2 1 2 N N N N 2 1
10 5611/13 60 1 2 10 7*4*2.5 1 1 2 N Y Y Y 4 2
11 5814/13 45 2 2 3 6*4*1 2 1 1 N Y Y Y 4 1
12 5969/13 53 1 2 3 6*4*1.5 1 1 1 N Y N Y 4 1
13 7235/13 66 1 2 10 3.5*2.5*1 1 1 2 Y Y Y Y 4 1
14 7424/13 43 1 2 2 10*5*5 1 2 2 Y N N N 2 1
15 7597/13 51 1 2 3 5*4*2 1 1 2 Y Y Y Y 3 1
16 7739/13 55 1 2 3 4*4*1 1 1 2 N N N N 1 1
17 8330/13 29 1 1 1 9*7*4 1 1 2 Y Y Y Y 4 1
18 8523/13 47 2 2 3 5*4*1 1 1 1 N N N N 1 1
19 8618/13 56 1 2 3 6*4*2 1 1 2 N N N N 1 1
20 9552/13 52 1 1 1 10*9*4 1 1 2 Y Y Y Y 4 1
21 9860/13 50 1 2 4 7*3*1.5 2 1 2 N Y N Y 4 1
22 10203/13 65 1 1 1 3*2*0.5 1 1 1 N Y Y Y 4 1
23 10414/13 55 1 2 2 6*5*1 1 1 2 Y N N N 1 1
24 10507/13 40 2 1 1 4*3*1.5 4 3 2 N Y Y Y 4 1
25 10641/13 65 1 2 3 5*4*1 1 1 3 N Y Y Y 4 1
26 11100/13 58 2 1 1 13*10*5 1 2 2 N N N N 1 1
27 11075/13 55 1 2 9 4*3*2 6 1 1 N N N N 1 1
S.No HPE No Age Gender Location P/D Size Gross HPE Grade LCI LI VI LN Mets MAC Margins VEGF
28 11135/13 65 2 1 1 4*2*1 1 1 2 Y N N N 2 1
29 2689/13 55 2 2 4 1.5*1*1 3 1 2 Y N N N 1 1
30 2856/13 23 1 1 1 8*6*3 1 4 3 N Y Y Y 4 1
31 3114/13 35 2 2 4 3*2*1 3 3 2 N Y Y Y 4 1
32 3194/13 60 1 1 1 10*7*2 1 1 2 Y N N N 1 1
33 3482/13 46 1 2 4 1.5*1*0.5 3 1 2 N N N N 1 1
34 3528/13 53 1 2 3 3*2.5*1 2 1 2 N Y Y Y 4 1
35 4265/13 57 1 1 8 7*5*2 1 1 2 N N N N 2 1
36 4467/13 75 1 2 3 2*1.5*1 2 1 2 Y N N N 1 1
37 4938/13 70 1 2 4 2.5*2.5*1 1 1 2 N Y Y Y 4 1
38 5209/13 45 1 2 4 4*2.5*1 1 1 2 N Y Y Y 4 1
39 5542/13 33 1 2 3 6*3*1 1 4 2 N Y N Y 4 1
40 6272/13 40 2 2 7 4*3*1.5 1 1 2 N N N N 2 1
41 7991/13 34 1 2 2 9*8*3 1 3 2 N N N N 2 1
42 8208/13 60 1 2 3 5*4*2 1 1 2 Y N N N 1 1
43 8840/13 28 2 2 4 3.5*3.5*1 1 1 2 N Y Y Y 4 1
44 10654/13 55 2 2 4 2.5*1*1 1 1 2 Y N N N 1 1
45 10665/13 62 2 1 1 8*4*4 1 1 2 Y N N N 1 1
46 11024/13 38 1 2 1 6*3*1 2 1 2 N N N N 1 1
47 11126/13 53 1 2 7 6*4*2 2 3 2 N N N N 2 1
48 11203/13 72 1 2 11 7*6*0.5 1 1 2 N Y N Y 3 1
49 30/14 72 1 1 1 6*6*1 1 5 3 N Y Y Y 4 1
50 180/14 70 1 2 3 2*1*0.5 3 1 2 N Y Y Y 4 2
51 1006/14 55 2 1 1 3*1*0.5 5 1 2 Y N N N 2 1
52 1041/14 52 2 2 3 3*2*1 2 1 2 Y N N N 2 1
53 740/14 51 2 1 10 3*3*2 1 1 2 Y Y Y Y 3 1 2+
54 869/14 58 1 2 4 3*2*1 2 1 2 N N N N 2 1
S.No HPE No Age Gender Location P/D Size Gross HPE Grade LCI LI VI LN Mets MAC Margins VEGF
55 920/14 40 2 2 3 2*2*0.5 1 1 2 N Y Y Y 4 1
56 1653/14 42 1 1 1 15*10*5 1 1 3 Y Y Y Y 4 1
57 1695/14 28 2 2 3 4*4*3 1 1 1 Y Y Y Y 4 1 2+
58 1892/14 47 2 2 2 5*2.5*1 1 1 1 Y N N N 1 1
59 3263/14 58 2 2 3 8*2*1 1 1 1 N Y Y Y 3 1 3+
60 3385/14 70 1 2 3 0.5*0.5*0.5 2 1 1 Y N N N 1 1
61 4360/14 49 2 2 4 5*3*2 2 1 1 Y N N N 2 1
62 4417/14 39 2 2 4 8*8*2 1 1 3 N Y Y Y 4 2
63 4509/14 65 2 2 7 1.5*1*0.5 3 1 2 N N N N 2 1
64 4810/14 60 1 2 6 9*9*2 1 1 1 Y N N N 2 1
65 5179/14 59 2 1 1 3*2*1 1 1 2 N Y Y Y 4 1 3+
66 5830/14 47 1 2 5 10*7*1.5 1 1 2 Y Y Y Y 4 1
67 6069/14 54 1 2 6 8*8*1.5 4 1 1 Y Y N Y 4 1 3+
68 6153/14 60 1 2 3 4*3*1.5 1 1 3 N Y Y Y 4 2
69 6223/14 58 1 2 3 6*3*1.5 1 1 1 N Y Y Y 3 1 1+
70 6263/14 60 2 1 1 5*3*0.5 1 1 1 Y N N N 1 1
71 6402/14 55 2 2 3 2*1*0.5 1 1 2 N Y Y Y 3 1
72 6432/14 56 2 2 3 7*5*3 4 3 2 Y N N N 2 1
73 6781/14 65 1 2 2 10*10*2 1 3 2 Y N Y N 2 1 1+
74 6878/14 60 1 2 3 3.5*2*1.5 1 1 1 Y N N N 2 1
75 7249/14 33 1 1 1 5*4*2 4 3 2 N Y Y Y 4 1 2+
76 7310/14 38 1 2 7 6*5*2 2 1 2 N N N N 1 1
77 7536/14 51 2 2 5 5*4*1 3 1 2 Y Y Y Y 3 1 2+
78 7715/14 59 1 2 3 4*2*1 1 1 1 Y Y Y Y 4 1 3+
79 7935/14 62 1 2 5 5*5*1 3 1 2 Y Y Y Y 3 1 3+
80 8009/14 56 1 2 3 5*5*2 1 1 2 N N N N 2 1 1+
81 8133/14 60 2 2 3 6*3*2.5 1 1 2 N Y N Y 4 1
S.No HPE No Age Gender Location P/D Size Gross HPE Grade LCI LI VI LN Mets MAC Margins VEGF
82 8266/14 70 1 2 11 4.5*3*1 4 1 2 Y Y Y Y 4 1 3+
83 8569/14 35 1 1 1 5.5*5*3 2 1 2 N Y Y Y 4 1
84 8812/14 47 2 1 1 6*3*1 1 1 2 Y N Y N 1 1 1+
85 8928/14 46 1 2 6 3*2*1 2 1 2 N Y Y Y 3 1 2+
86 9173/14 35 1 2 3 2*1*0.5 6 3 2 N N N N 1 1
87 9256/14 50 2 2 3 7*2*1 4 3 2 N N N N 1 1
88 9581/14 32 1 1 1 4*3*0.5 2 1 2 Y N N N 1 1
89 9929/14 43 2 2 2 5*3*1 1 1 2 N Y N Y 4 1 3+
90 10249/14 75 2 1 1 10*6*2 1 1 1 Y N N N 2 1 2+
91 10300/14 60 2 2 6 5*5*1 1 1 2 Y Y Y Y 4 1 3+
92 10829/14 79 2 2 3 3*3*1.5 1 2 1 Y Y Y Y 3 1 2+
93 11193/14 60 1 1 1 17*15*2 1 1 3 N Y Y Y 4 1 3+
94 11429/14 66 2 2 2 6*5*4 4 1 2 Y N N N 2 1
95 11545/14 57 1 2 3 3*2*1 3 3 2 N Y Y Y 3 1 1+
96 11854/14 45 1 2 2 9*4*2.5 4 1 1 Y N N N 1 1
97 1252/14 65 2 1 1 8*4*1 1 1 2 Y N N N 2 1 1+
98 1503/14 54 1 1 1 11*8*2 1 1 2 Y N N N 2 1
99 2659/14 60 2 1 1 2*1*0.5 2 1 2 Y N N N 2 1
100 2777/14 80 2 2 9 4*4*1 3 1 2 N Y N Y 4 1
101 3090/14 40 1 1 1 5*3*2 1 3 2 Y N N N 1 1
102 3199/14 59 2 2 9 7*5*1 1 1 2 Y N N N 1 1
103 3428/14 58 1 2 3 1*1*0.5 2 1 1 Y N N N 1 1
104 3871/14 57 1 1 1 6*5*1.5 1 1 1 Y N N N 1 1
105 4030/14 55 2 2 4 4*3*0.5 1 1 1 Y Y Y N 2 1 3+
106 5307/14 65 2 1 1 5*4*1 1 1 1 Y N N N 1 1 1+
107 5543/14 55 1 2 2 3*3*1 1 1 1 N Y Y Y 4 1
108 6033/14 46 1 2 3 2*1*0.5 2 1 2 Y Y N Y 4 1
S.No HPE No Age Gender Location P/D Size Gross HPE Grade LCI LI VI LN Mets MAC Margins VEGF
109 6113/14 51 1 2 3 1*1*0.5 2 1 2 N N N N 2 1
110 6384/14 50 1 1 1 6*4*2 1 1 3 Y N N N 2 1
111 7033/14 66 2 1 1 2*1*0.5 5 1 2 Y Y Y Y 4 1
112 7809/14 52 2 1 1 7*6*1 1 1 2 Y N N N 2 1
113 8866/14 76 1 2 11 3*3*0.5 1 1 2 N Y Y N 2 1 2+
114 9754/14 65 2 2 6 4*2*1 2 1 2 N Y N Y 4 1 2+
115 10640/14 62 1 1 1 10*8*1.5 1 1 3 Y Y Y Y 4 1 2+
116 10807/14 60 1 1 1 2*1*0.5 1 1 2 Y N N N 2 1
117 11316/14 70 1 2 2 5.5*5*1 1 1 2 N Y N N 2 1 2+
118 11984/14 34 2 1 1 12*7*1.5 3 2 1 Y Y Y Y 4 1
119 1/15 40 2 2 2 14*10*2 4 1 3 N N N N 2 1
120 640/15 33 2 2 3 10*5.5*3 1 4 3 N Y Y N 2 1 3+
121 919/15 78 1 2 3 5*4*2.5 1 1 2 Y N Y N 2 1 3+
122 1144/15 75 2 2 3 8*5*1 1 1 2 Y Y N N 2 1 3+
123 302/15 42 1 2 3 6*4*1 1 1 3 N Y Y Y 4 1 3+
124 786/15 55 2 2 3 7*3*2.5 1 1 2 Y N Y N 2 1 1+
125 1281/15 73 1 1 1 9*6*4 1 1 2 N Y Y Y 4 1 3+
126 1601/15 75 1 2 4 8*4.5*1 6 1 1 Y N N N 1 1 3+
127 1793/15 56 2 2 3 3*3*0.5 1 1 2 Y Y Y Y 3 1 2+
128 2057/15 61 1 2 3 2*2*0.5 3 1 2 Y Y Y N 2 1 2+
129 2224/15 46 1 2 3 9*9*1 1 1 1 Y N N N 1 1
130 2230/15 75 2 2 6 5*5*1 1 1 1 N N Y N 2 1 2+
131 2461/15 55 2 2 9 4*3*1.5 6 1 2 N Y N Y 4 1 3+
132 2557/15 55 1 1 1 10*8*3 1 1 1 Y N N N 1 1
133 1578/15 57 2 1 1 3*2.5*1 2 1 1 Y N N N 2 1
134 1673/15 43 1 1 1 8*5*5 1 1 1 Y N N N 2 1
135 1875/15 49 2 1 1 5*3*1 4 3 2 Y N N N 2 1
S.No HPE No Age Gender Location P/D Size Gross HPE Grade LCI LI VI LN Mets MAC Margins VEGF
136 2120/15 63 1 2 3 7*6*2 1 1 3 Y Y Y Y 4 1
137 2546/15 60 2 2 3 6*4*2 1 1 2 Y N Y N 2 1 2+
138 2815/15 51 1 2 11 3*2*1 4 1 2 Y N Y N 2 1 2+
139 2819/15 50 2 1 1 10*8*6 4 2 2 Y Y N N 1 1 1+
140 2895/15 55 2 2 10 10*5*2 1 1 3 N Y Y Y 4 1 3+
141 1578/15 57 2 1 1 3*2.5*1 4 1 1 N N N N 2 1 2+
142 4737/15 44 2 1 1 4*3*1 1 1 1 Y N Y N 2 1 2+
143 3857/15 60 1 2 3 6*5*1 1 1 1 N Y Y Y 4 1 3+
144 4371/15 63 1 2 3 3.5*3*1 4 1 2 Y Y Y Y 4 1 3+
145 2224/15 46 1 2 4 9*9*1 1 1 1 Y Y Y N 1 1 2+
146 4368/15 52 1 2 3 6.5*5*1 2 1 1 N Y Y Y 4 1 3+
147 4742/15 57 1 1 1 6*5*1 1 3 2 N Y N Y 4 1 2+
 
